Clinical Studies and Case Reports

On this site you will find clinical studies with cannabis or single cannabinoids in different diseases and case reports on the use of cannabis by patients.
You may search for diseases (indications), authors, medication, study design (controlled study, open trial, case report etc.) and other criteria.




[Back to Overview]  [IACM Homepage]

TitleA double-blind, controlled trial of nabilone vs. prochlorperazine for refractory emesis induced by cancer chemotherapy.
Author(s)Johansson R, Kilkku P, Groenroos M.
Journal, Volume, IssueCancer Treat Rev. 1982 Dec;9 Suppl B:25-33.
Major outcome(s)Severity of nausea and number of vomiting ejections and dry retching episodes were significantly less under nabilone.
IndicationCancer;Cancer chemotherapyAbstract
MedicationNabilone

27 patients who were refractory to previously used common antiemetic treatment while on chemotherapy have been entered in a crossover, double-blind, randomized study aimed to compare efficacy and toxicity of 2 mg b.i.d. oral nabilone and 10 mg b.i.d. oral prochlorperazine. Eighteen patients are presently evaluable for efficacy. Severity of nausea was less during the nabilone period of administration. The number of vomiting ejections and dry retching episodes was significantly less (P<0.001) on nabilone than on prochlorperazine. There was a significant period effect (P<0.01) together with the patientís evaluation of vomiting episodes and the investigatorís assessment of therapeutic efficacy, the vomiting scores being worse during the second treatment period. 72% of the patients (P<0.05) preferred nabilone to prochlorpearzine, in agreement with the observed therapeutic efficacy. Side effects (54%) were more frequent and severe with nabilone than with prochlorperazine; postural hypotension (42%), which was severe in 7 patients with a fall of more than 30 mm Hg. Vertigo (23%), CNS changes (headache, depression, general weakness-4%; mood alterations with dysphoria-8%). Nabilone showed activity against cis-platinum- (50 mg/m2) and adriamycin-plus-cyclophosphamide-induced vomiting

Route(s)Oral
Dose(s)
Duration (days)
Participants27 patients on chemotherapy.
DesignControlled study
Type of publicationMedical journal
Address of author(s)
Full text

[Back to Overview]  [IACM Homepage]


up